Exabis Library
Welcome to the e-CCO Library!
P372: Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P372: Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCU
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P372: Endoscopic ultrasonography in the differential diagnosis of Ulcerative colitis and Crohn's disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P372: Neurological symptoms and imaging abnormalities in brain MRI in patients with Crohn’s disease receiving anti-TNFa therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P372: The long term course of patients undergoing ileal pouch-anal anastomosis for ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P373: Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P373: An Unusual Occurrence of Right-sided Colonic Neuroendocrine Carcinoma in Ulcerative Colitis – A case report
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P373: Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P373: Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P373: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P373: Real-file prospective experience with adalimumab in inducing remission in ulcerative colitis in Italian primary inflammatory bowel diseases centres
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P374 Disease course and fate of Crohn’s perianal fistula patients following failure of initial biologic therapy: real-world lessons on the impact of refractory disease from a tertiary centre cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P374: Efficacy of a micronised, dispersible ferric pyrophosphate in children with anaemia associated with inflammatory bowel disease.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P374: Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P374: Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P374: Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P374: Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM